IMPAACT 2001 Prohibited and Precautionary Medications

As our understanding of drug interactions continues to grow as new information becomes available, the following information may not be all-inclusive. Consultation with the most recent prescribing information, package inserts, and the drug interaction websites listed below is advised when determining the significance of potential drug interactions. Any questions regarding medications that are not included within this document should be emailed to the IMPAACT 2001 Core Team for approval (impaact.core2001@fstrf.org).

Helpful Websites for information on Drug Interactions:
- HIV Drug Interactions: http://www.hiv-druginteractions.org/
- inPractice: http://www.inpractice.com

Precautionary Medications
The following medications should be avoided, if possible, and alternative treatments sought. Please notify the IMPAACT 2001 Core Team if treatment with any of these medications is necessary for clinical care.

- Alprazolam
- Aprepitant
- Atorvastatin
- Colchicine
- Eliglustat
- Pimozide
- Rivaroxaban
- Tadalafil

Prohibited Medications
The following medications/therapies are prohibited in this study:
- Protease Inhibitor (PI) and entry inhibitor based antiretroviral therapy (ART) regimens
- Nevirapine
- Etravirine
- Rilpivirine
- Didanosine (DDI)
- Stavudine (D4T)
- Alfentanil
- Avanafil
- Budesonide
- Buspirone
- Conivaptan
- Darifenacin
- Darunavir
- Dasatinib
- Dronedarone
- Ebastine
- Eletriptan
- Eplerenone
- Everolimus
- Felodipine
- Ibrutinib
- Indinavir
Lomitapide
Lovastatin
Lurasidone
Maraviroc
Midazolam
Naloxegol
Nisoldipine
Quetiapine
Saquinavir
Sildenafil
Simvastatin
Sirolimus
Tacrolimus
Ticagrelor
Tipranavir
Tolvaptan
Triazolam
Vardenafil